Want to see CTMX full AI Analyst Report?
CTMX Stock Chart & Stats
$3.24
-$0.09(-2.70%)
At close: 4:00 PM EDT
$3.24
-$0.09(-2.70%)
Day’s Range― - ―
52-Week Range$1.72 - $8.21
Previous CloseN/A
Volume1.52M
Average Volume (3M)5.08M
Market Cap
$753.93M
Enterprise Value$495.53
Total Cash (Recent Filing)$330.28M
Total Debt (Recent Filing)$5.70M
Price to Earnings (P/E)―
Beta2.61
Next Earnings
Nov 10, 2026EPS Estimate
-0.07Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.45
Shares Outstanding217,899,280
10 Day Avg. Volume3,823,161
30 Day Avg. Volume5,083,822
Financial Highlights & Ratios
PEG Ratio0.20
Price to Book (P/B)5.93
Price to Sales (P/S)7.71
P/FCF Ratio-7.75
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$11.67Price Target Upside260.08% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering6
EPS Forecast (FY)-0.42
Revenue Forecast (FY)$32.10M
Bulls Say, Bears Say
Bulls Say
Strong Cash RunwayA large cash balance and explicit runway into H2 2028 materially reduces near-term financing pressure and gives management time to execute registrational work on Varseta‑M, advance combinations and CX‑801, and prioritize capital allocation without forcing immediate dilution.
Expanded Regeneron CollaborationAn enlarged, high-value partnership with Regeneron validates the Probody platform, creates substantial non-dilutive milestone potential, and diversifies future revenue streams; structural partner support also helps derisk development and commercialisation paths over the medium term.
Promising Varseta‑M Clinical EfficacyDurable clinical efficacy materially above existing late-line standards increases likelihood of a successful registrational program, supports a differentiated positioning for an EpCAM ADC, and underpins potential for label expansion and higher commercial value if safety/tolerability are managed.
Bears Say
Sustained Negative Cash Flow / BurnOngoing negative operating and free cash flow demonstrates the company is not self-funding R&D; sustaining multiple clinical programs will continue to consume cash and could require future financings or milestone reliance, pressuring shareholder dilution and strategic flexibility.
Volatile, Declining Revenue BaseRevenue is lumpy and dependent on collaboration milestones rather than recurring product sales, producing large year-over-year swings that complicate forecasting and increase reliance on partner payments or equity raises to fund operations absent commercialized products.
Clinical Safety And Dose‑selection RiskSafety concerns and unresolved dose selection create structural regulatory and commercial risk: if Grade 3 events or tolerability prevent selecting an optimal registrational dose, trial design, label restrictions and physician uptake could be materially impaired even if efficacy remains strong.
CytomX Therapeutics News
CTMX FAQ
What was CytomX Therapeutics Inc.’s price range in the past 12 months?
CytomX Therapeutics Inc. lowest stock price was $1.72 and its highest was $8.21 in the past 12 months.
What is CytomX Therapeutics Inc.’s market cap?
CytomX Therapeutics Inc.’s market cap is $753.93M.
When is CytomX Therapeutics Inc.’s upcoming earnings report date?
CytomX Therapeutics Inc.’s upcoming earnings report date is Nov 10, 2026 which is in 91 days.
How were CytomX Therapeutics Inc.’s earnings last quarter?
CytomX Therapeutics Inc. released its earnings results on Aug 06, 2026. The company reported -$0.09 earnings per share for the quarter, missing the consensus estimate of -$0.077 by -$0.013.
Is CytomX Therapeutics Inc. overvalued?
According to Wall Street analysts CytomX Therapeutics Inc.’s price is currently Undervalued.
Does CytomX Therapeutics Inc. pay dividends?
CytomX Therapeutics Inc. does not currently pay dividends.
What is CytomX Therapeutics Inc.’s EPS estimate?
CytomX Therapeutics Inc.’s EPS estimate is -0.07.
How many shares outstanding does CytomX Therapeutics Inc. have?
CytomX Therapeutics Inc. has 217,899,280 shares outstanding.
What happened to CytomX Therapeutics Inc.’s price movement after its last earnings report?
CytomX Therapeutics Inc. reported an EPS of -$0.09 in its last earnings report, missing expectations of -$0.077. Following the earnings report the stock price went up 2.671%.
Which hedge fund is a major shareholder of CytomX Therapeutics Inc.?
Currently, no hedge funds are holding shares in CTMX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
CytomX Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$11.67 (260.08% Upside)
$11.67 (260.08% Upside)
Blogger Sentiment
Bullish
CTMX Sentiment 67%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 1.9M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $5.0K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.1%
Last 30 Days ▼ 3.2%
Last 30 Days ▼ 3.2%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
35.56%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
264.84%
Trailing 12-Months
Company Description
CytomX Therapeutics Inc.
CytomX Therapeutics, Inc. is a United States-based biopharmaceutical company primarily focused on creating treatments for cancer. The company utilizes its proprietary Probody technology platform to engineer targeted antibody therapeutics for oncological applications. Its robust clinical pipeline includes several notable drug candidates. CX-2009, an antibody-drug conjugate (ADC) designed to target CD166, is currently in Phase II clinical trials for treating breast cancer. Another investigational therapy, CX-2029, has also reached Phase II trials, where it is being evaluated for various cancers such as squamous non-small cell lung cancer, head and neck squamous cell carcinoma, esophageal and gastro-esophageal junction cancers, and diffuse large B-cell lymphoma. Additionally, CytomX is progressing two CTLA-4 Probody therapeutics: BMS-986249, which is undergoing Phase I/II clinical trials for metastatic melanoma, and BMS-986288, in Phase I trials for solid tumors. Beyond these, the company is developing CX-2043, a conditionally activated ADC targeting the epithelial cell adhesion molecule, and CX-904, a conditionally activated epidermal growth factor receptor, both aimed at addressing solid tumor conditions. CytomX has forged strategic partnerships with leading pharmaceutical firms, including AbbVie Ireland Unlimited Company, Amgen, Inc., Bristol-Myers Squibb Company, ImmunoGen, Inc., Pfizer Inc., and Astellas Pharma Inc., to collaboratively advance its Probody therapeutics. The company was founded in 2008 and its main office is located in South San Francisco, California.
CTMX Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call emphasized substantial clinical progress and clear near-term development and regulatory plans for Varseta-M (robust ORR 20%–32% and ~7 months PFS, completed optimization enrollment, combination and expansion strategies), backed by a materially strengthened balance sheet (cash up ~152.9%) and runway into H2 2028. Key risks remain operational and clinical: a large year-over-year revenue decline driven by completed collaborations, modest increases in operating costs, and the need to confirm that Grade 3 diarrhea can be reliably managed in the full optimization cohort and over longer follow-up. Overall, the positive clinical momentum and strong cash position outweigh the near-term financial and clinical uncertainties.View all CTMX earnings summariesCTMX Stock 12 Month Forecast
Average Price Target
$11.67
▲(260.08% Upside)
Technical Analysis
Ownership Overview
0.96% Insiders
15.49% Mutual Funds
0.59% Other Institutional Investors
68.86% Public Companies and
Individual Investors